Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1977 5
1978 7
1979 5
1980 6
1981 10
1982 6
1983 2
1984 5
1985 5
1986 4
1987 8
1988 7
1989 2
1990 7
1991 4
1992 2
1994 1
1995 2
1996 2
2003 1
2005 4
2006 3
2007 1
2008 4
2009 2
2011 3
2012 2
2013 1
2014 4
2015 5
2017 2
2018 2
2019 3
2020 3
2021 6
2022 6
2023 3
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Gottlieb RL, et al. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Ogbuagu O, et al. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. Lancet HIV. 2021. PMID: 34197772 Clinical Trial.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Among authors: flamm ja. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
Cardiovascular Disease Risk Factor Control in People With and Without HIV.
Silverberg MJ, Levine TM, Lea AN, Williams AE, Alexeeff SE, Bryant K, Cavassini M, Flamm JA, Hare CB, Ingle SM, Justice AC, Lam JO, Sterling SA, Horberg MA, Satre DD. Silverberg MJ, et al. Among authors: flamm ja. Clin Infect Dis. 2024 May 15;78(5):1264-1271. doi: 10.1093/cid/ciad728. Clin Infect Dis. 2024. PMID: 38227614
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP, Czarnogorski M, Dalessandro M, D'Amico R, Nwafor T, Williams W, Merrill D, Wang Y, Stassek L, Wohlfeiler MB, Sinclair GI, Mena LA, Thedinger B, Flamm JA, Benson P, Spreen WR. Garris CP, et al. Among authors: flamm ja. J Int AIDS Soc. 2022 Sep;25(9):e26006. doi: 10.1002/jia2.26006. J Int AIDS Soc. 2022. PMID: 36097674 Free PMC article. Clinical Trial.
Racial, ethnic, and age disparities in the association of mental health symptoms and polysubstance use among persons in HIV care.
Davy-Mendez T, Sarovar V, Levine-Hall T, Lea AN, Leibowitz AS, Luu MN, Flamm JA, Hare CB, Dumoit Smith J, Iturralde E, Dilley J, Silverberg MJ, Satre DD. Davy-Mendez T, et al. Among authors: flamm ja. PLoS One. 2023 Nov 28;18(11):e0294483. doi: 10.1371/journal.pone.0294483. eCollection 2023. PLoS One. 2023. PMID: 38015975 Free PMC article.
[Kidney spindle-cell sarcoma].
Flamm J, Wöber L. Flamm J, et al. Z Urol Nephrol. 1978 Feb;71(2):123-7. Z Urol Nephrol. 1978. PMID: 645245 German. No abstract available.
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K. Wohl DA, et al. Among authors: flamm j. Lancet HIV. 2024 Aug;11(8):e508-e521. doi: 10.1016/S2352-3018(24)00130-9. Epub 2024 Jul 14. Lancet HIV. 2024. PMID: 39008999 Clinical Trial.
Factors associated with suicidal ideation among people with HIV engaged in care.
Satre DD, Sarovar V, Levine T, Leibowitz AS, Lea AN, Ridout KK, Hare CB, Luu MN, Flamm J, Dilley JW, Davy-Mendez T, Sterling SA, Silverberg MJ. Satre DD, et al. Among authors: flamm j. J Affect Disord. 2024 Aug 1;358:369-376. doi: 10.1016/j.jad.2024.05.036. Epub 2024 May 7. J Affect Disord. 2024. PMID: 38723683
145 results